Literature DB >> 19215821

Radiation-induced thymidine phosphorylase upregulation in rectal cancer is mediated by tumor-associated macrophages by monocyte chemoattractant protein-1 from cancer cells.

Tae-Dong Kim1, Ge Li, Kyoung-Sub Song, Jin-Man Kim, Jun-Sang Kim, Jong-Seok Kim, Eun-Jin Yun, Jong-Il Park, Hae-Duck Park, Byung-Doo Hwang, Kyu Lim, Wan-Hee Yoon.   

Abstract

PURPOSE: The mechanisms of thymidine phosphorylase (TP) regulation induced by radiation therapy (XRT) in various tumors are poorly understood. We investigated the effect and mechanisms of preoperative XRT on TP expression in rectal cancer tissues. METHODS AND MATERIALS: TP expression and CD68 and monocyte chemoattractant protein-1 (MCP-1) levels in rectal cancer tissues and cancer cell lines were evaluated before and after XRT in Western blotting, immunohistochemistry, enzyme-linked immunoassay, and reverse transcription-polymerase chain reaction studies. Isolated peripheral blood monocytes were used in the study of chemotaxis under the influence of MCP-1 released by irradiated colon cancer cells.
RESULTS: Expression of TP was significantly elevated by 9 Gy of XRT in most rectal cancer tissues but not by higher doses of XRT. In keeping with the close correlation of the increase in both TP expression and the number of tumor-associated macrophages (TAMs), anti-TP immunoreactivity was found in the CD68-positive TAMs and not the neoplastic cells. Expression of MCP-1 was increased in most cases after XRT, and this increase was strongly correlated with TP expression. However, this increase in MCP-1 expression occurred in tumor cells and not stromal cells. The XRT upregulated MCP-1 mRNA and also triggered the release of MCP-1 protein from cultured colon cancer cells. The supernatant of irradiated colon cancer cells showed strong chemotactic activity for monocyte migration, but this activity was completely abolished by neutralizing antibody.
CONCLUSIONS: Use of XRT induces MCP-1 expression in cancer cells, which causes circulating monocytes to be recruited into TAMs, which then upregulate TP expression in rectal cancer tissues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19215821     DOI: 10.1016/j.ijrobp.2008.07.068

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

Review 1.  Oxidative DNA damage caused by inflammation may link to stress-induced non-targeted effects.

Authors:  Carl N Sprung; Alesia Ivashkevich; Helen B Forrester; Christophe E Redon; Alexandros Georgakilas; Olga A Martin
Journal:  Cancer Lett       Date:  2013-09-14       Impact factor: 8.679

Review 2.  TAS-102: a novel antimetabolite for the 21st century.

Authors:  Nataliya Uboha; Howard S Hochster
Journal:  Future Oncol       Date:  2015-11-30       Impact factor: 3.404

3.  Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.

Authors:  Lindsay B Kilburn; Mehmet Kocak; Franziska Schaedeli Stark; Georgina Meneses-Lorente; Carrie Brownstein; Sazzad Hussain; Murali Chintagumpala; Patrick A Thompson; Sri Gururangan; Anuradha Banerjee; Arnold C Paulino; Larry Kun; James M Boyett; Susan M Blaney
Journal:  Neuro Oncol       Date:  2013-04-16       Impact factor: 12.300

4.  Analysis of chemokine and chemokine receptor expression in squamous cell carcinoma of the head and neck (SCCHN) cell lines.

Authors:  Hendrik A Wolff; David Rolke; Margret Rave-Fränk; Markus Schirmer; Wolfgang Eicheler; Annegret Doerfler; Andrea Hille; Clemens F Hess; Christoph Matthias; Ralph M W Rödel; Hans Christiansen
Journal:  Radiat Environ Biophys       Date:  2010-11-18       Impact factor: 1.925

Review 5.  Macrophage biology plays a central role during ionizing radiation-elicited tumor response.

Authors:  Qiuji Wu; Awatef Allouch; Isabelle Martins; Nazanine Modjtahedi; Eric Deutsch; Jean-Luc Perfettini
Journal:  Biomed J       Date:  2017-07-29       Impact factor: 4.910

6.  Thymidine Phosphorylase Gene Expression in Stage III Colorectal Cancer.

Authors:  Elinor B Lindskog; Yvonne Wettergren; Elisabeth Odin; Bengt Gustavsson; Kristoffer Derwinger
Journal:  Clin Med Insights Oncol       Date:  2012-10-15

Review 7.  Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer.

Authors:  Tingting Liang; Weihua Tong; Siyang Ma; Pengyu Chang
Journal:  Oncoimmunology       Date:  2020-06-03       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.